JFL Life Sciences confirms no encumbrance by promoters in FY26
JFL Life Sciences disclosed that its promoters and promoter group did not create any new encumbrances on shares during FY 2025-2026, complying with SEBI Takeover Regulations. The confirmation, signed by Smiral Ashwinkumar Patel, was submitted to the NSE on April 04, 2025.
*this image is generated using AI for illustrative purposes only.
JFL Life Sciences disclosed that its promoters and promoter group have not created any encumbrance on their shares during the financial year 2025-2026. The confirmation was submitted to the National Stock Exchange on April 04, 2025, in compliance with Regulation 31(4) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. The disclosure ensures transparency regarding the shareholding status of the key stakeholders.
The letter, addressed to the Manager of the Listing Department at the National Stock Exchange of India Limited, was signed by Smiral Ashwinkumar Patel on behalf of the promoter and promoter group. It explicitly states that no encumbrance was made directly or indirectly, other than those already disclosed.
Promoter and Promoter Group Details
The disclosure identified the individuals comprising the promoter and promoter group of JFL Life Sciences.
| SRN | Name |
|---|---|
| Promoter | |
| 1 | SMIRAL ASHWINKUMAR PATEL |
| Promoter group | |
| 1 | SMIRAL ASHWINKUMAR PATEL HUF |
| 2 | ASHWINBHAI JIVRAMBHAI PATEL |
| 3 | TEJAL SMIRAL PATEL |
| 4 | ASHOKKUMAR PARSHOTTAMDAS PATEL |
| 5 | RUPESH KIRTIBHAI PATEL |
| 6 | KIRTIKUMAR PARSHOTTAMBHAI PATEL |
| 7 | SHOBHNABEN KIRTIKUMAR PATEL |
| 8 | ARTIBEN MANISHKUMAR PATEL |
| 9 | PATEL DAKSHABEN |
| 10 | USHABEN ASHOKKUMAR PATEL |
The filing confirms adherence to the regulatory requirements aimed at monitoring the pledging or encumbrance of shares by promoters.
Historical Stock Returns for JFL Life Sciences
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.08% | -3.17% | 0.0% | -28.24% | -42.81% | -78.70% |
How might this clean shareholding status influence investor confidence and the stock's liquidity in the upcoming quarter?
Does the lack of encumbrance suggest the promoters are positioning for potential capital raising or M&A activity?
How does JFL Life Sciences' zero-pledge status compare to the industry average for the pharmaceutical sector?
17
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
